Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

INTRODUCTION: Lazertinib is a potent, irreversible, brain-penetrant, mutant-selective, and wild-type–sparing third-generation EGFR tyrosine kinase inhibitor (TKI), creating a wide therapeutic index. Cardiovascular adverse events (AEs), including QT prolongation, decreased left ventricular ejection f...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Seong Bok, Kim, Kyeong Bae, Sim, Sujin, Cho, Byoung Chul, Ahn, Myung-Ju, Han, Ji-Youn, Kim, Sang-We, Lee, Ki Hyeong, Cho, Eun Kyung, Haddish-Berhane, Nahor, Mehta, Jaydeep, Oh, Se-Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501499/
https://www.ncbi.nlm.nih.gov/pubmed/34647107
http://dx.doi.org/10.1016/j.jtocrr.2021.100224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501499/
https://www.ncbi.nlm.nih.gov/pubmed/34647107
http://dx.doi.org/10.1016/j.jtocrr.2021.100224

Ejemplares similares